The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer

Brendon M. Stiles, Amit Bhargava, Prasad S. Adusumilli, Stephen F. Stanziale, Teresa H. Kim, Valerie W. Rusch, Yuman Fong

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background. The oncolytic herpes simplex-1 virus, NV1066, is a replication-competent virus that has been engineered to infect and lyse tumor cells selectively and to carry a transgene for enhanced green fluorescent protein (EGFP). The purpose of this study was to determine viral cytotoxicity in an esophageal cancer cell line and to determine whether EGFP expression could be used as a marker of viral infection. Methods. BE3 esophageal adenocarcinoma cells were infected with NV1066 in vitro to determine cell kill and viral replication. EGFP expression was assessed by flow cytometry. The in vivo anti-tumor activity of NV1066 was tested in subcutaneous and intraperitoneal xenograft models. EGFP expression was localized in vivo by fluorescent microscopy and fluorescent laparoscopy. Results. NV1066 effectively replicated within and killed BE3 cells in vitro and in vivo. EGFP expression identified infected tumor cells. After NV1066 treatment in vivo, EGFP expression localized to the tumor. In an intraperitoneal tumor model, EGFP could be visualized endoscopically using a laparoscope with a fluorescent filter. Conclusion. NW1066 has oncolytic activity against the BE3 cell line and may be a useful therapy against esophageal cancer. EGFP expression localizes the virus and may help to identify tumor deposits in vivo. Oncolytic activity with NV1066 against gastrointestinal cancers may potentially be tracked by endoscopy.

Original languageEnglish (US)
Pages (from-to)357-364
Number of pages8
JournalSurgery
Volume134
Issue number2
DOIs
StatePublished - Aug 1 2003

Fingerprint

Oncolytic Viruses
Simplexvirus
Esophageal Neoplasms
Neoplasms
Laparoscopes
Cell Line
Herpes Simplex
Gastrointestinal Neoplasms
enhanced green fluorescent protein
Virus Diseases
Virus Replication
Transgenes
Heterografts
Laparoscopy
Endoscopy
Flow Cytometry
Adenocarcinoma
Viruses

ASJC Scopus subject areas

  • Surgery

Cite this

Stiles, B. M., Bhargava, A., Adusumilli, P. S., Stanziale, S. F., Kim, T. H., Rusch, V. W., & Fong, Y. (2003). The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery, 134(2), 357-364. https://doi.org/10.1067/msy.2003.244

The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. / Stiles, Brendon M.; Bhargava, Amit; Adusumilli, Prasad S.; Stanziale, Stephen F.; Kim, Teresa H.; Rusch, Valerie W.; Fong, Yuman.

In: Surgery, Vol. 134, No. 2, 01.08.2003, p. 357-364.

Research output: Contribution to journalArticle

Stiles, BM, Bhargava, A, Adusumilli, PS, Stanziale, SF, Kim, TH, Rusch, VW & Fong, Y 2003, 'The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer', Surgery, vol. 134, no. 2, pp. 357-364. https://doi.org/10.1067/msy.2003.244
Stiles, Brendon M. ; Bhargava, Amit ; Adusumilli, Prasad S. ; Stanziale, Stephen F. ; Kim, Teresa H. ; Rusch, Valerie W. ; Fong, Yuman. / The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. In: Surgery. 2003 ; Vol. 134, No. 2. pp. 357-364.
@article{298298ae56a94b818dbf74525219ee1d,
title = "The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer",
abstract = "Background. The oncolytic herpes simplex-1 virus, NV1066, is a replication-competent virus that has been engineered to infect and lyse tumor cells selectively and to carry a transgene for enhanced green fluorescent protein (EGFP). The purpose of this study was to determine viral cytotoxicity in an esophageal cancer cell line and to determine whether EGFP expression could be used as a marker of viral infection. Methods. BE3 esophageal adenocarcinoma cells were infected with NV1066 in vitro to determine cell kill and viral replication. EGFP expression was assessed by flow cytometry. The in vivo anti-tumor activity of NV1066 was tested in subcutaneous and intraperitoneal xenograft models. EGFP expression was localized in vivo by fluorescent microscopy and fluorescent laparoscopy. Results. NV1066 effectively replicated within and killed BE3 cells in vitro and in vivo. EGFP expression identified infected tumor cells. After NV1066 treatment in vivo, EGFP expression localized to the tumor. In an intraperitoneal tumor model, EGFP could be visualized endoscopically using a laparoscope with a fluorescent filter. Conclusion. NW1066 has oncolytic activity against the BE3 cell line and may be a useful therapy against esophageal cancer. EGFP expression localizes the virus and may help to identify tumor deposits in vivo. Oncolytic activity with NV1066 against gastrointestinal cancers may potentially be tracked by endoscopy.",
author = "Stiles, {Brendon M.} and Amit Bhargava and Adusumilli, {Prasad S.} and Stanziale, {Stephen F.} and Kim, {Teresa H.} and Rusch, {Valerie W.} and Yuman Fong",
year = "2003",
month = "8",
day = "1",
doi = "10.1067/msy.2003.244",
language = "English (US)",
volume = "134",
pages = "357--364",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer

AU - Stiles, Brendon M.

AU - Bhargava, Amit

AU - Adusumilli, Prasad S.

AU - Stanziale, Stephen F.

AU - Kim, Teresa H.

AU - Rusch, Valerie W.

AU - Fong, Yuman

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background. The oncolytic herpes simplex-1 virus, NV1066, is a replication-competent virus that has been engineered to infect and lyse tumor cells selectively and to carry a transgene for enhanced green fluorescent protein (EGFP). The purpose of this study was to determine viral cytotoxicity in an esophageal cancer cell line and to determine whether EGFP expression could be used as a marker of viral infection. Methods. BE3 esophageal adenocarcinoma cells were infected with NV1066 in vitro to determine cell kill and viral replication. EGFP expression was assessed by flow cytometry. The in vivo anti-tumor activity of NV1066 was tested in subcutaneous and intraperitoneal xenograft models. EGFP expression was localized in vivo by fluorescent microscopy and fluorescent laparoscopy. Results. NV1066 effectively replicated within and killed BE3 cells in vitro and in vivo. EGFP expression identified infected tumor cells. After NV1066 treatment in vivo, EGFP expression localized to the tumor. In an intraperitoneal tumor model, EGFP could be visualized endoscopically using a laparoscope with a fluorescent filter. Conclusion. NW1066 has oncolytic activity against the BE3 cell line and may be a useful therapy against esophageal cancer. EGFP expression localizes the virus and may help to identify tumor deposits in vivo. Oncolytic activity with NV1066 against gastrointestinal cancers may potentially be tracked by endoscopy.

AB - Background. The oncolytic herpes simplex-1 virus, NV1066, is a replication-competent virus that has been engineered to infect and lyse tumor cells selectively and to carry a transgene for enhanced green fluorescent protein (EGFP). The purpose of this study was to determine viral cytotoxicity in an esophageal cancer cell line and to determine whether EGFP expression could be used as a marker of viral infection. Methods. BE3 esophageal adenocarcinoma cells were infected with NV1066 in vitro to determine cell kill and viral replication. EGFP expression was assessed by flow cytometry. The in vivo anti-tumor activity of NV1066 was tested in subcutaneous and intraperitoneal xenograft models. EGFP expression was localized in vivo by fluorescent microscopy and fluorescent laparoscopy. Results. NV1066 effectively replicated within and killed BE3 cells in vitro and in vivo. EGFP expression identified infected tumor cells. After NV1066 treatment in vivo, EGFP expression localized to the tumor. In an intraperitoneal tumor model, EGFP could be visualized endoscopically using a laparoscope with a fluorescent filter. Conclusion. NW1066 has oncolytic activity against the BE3 cell line and may be a useful therapy against esophageal cancer. EGFP expression localizes the virus and may help to identify tumor deposits in vivo. Oncolytic activity with NV1066 against gastrointestinal cancers may potentially be tracked by endoscopy.

UR - http://www.scopus.com/inward/record.url?scp=0041326572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041326572&partnerID=8YFLogxK

U2 - 10.1067/msy.2003.244

DO - 10.1067/msy.2003.244

M3 - Article

C2 - 12947341

AN - SCOPUS:0041326572

VL - 134

SP - 357

EP - 364

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 2

ER -